The Committee for Medicinal Products for Human Use of the European Medicines Agency recommended marketing authorization for Wezenla (ustekinumab) for the treatment of plaque psoriasis, including pediatric plaque psoriasis, psoriatic arthritis and Crohn’s disease.
The Group also gave its nod to tofidence (tocilizumab) for the treatment of rheumatoid arthritis, COVID-19, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis.
In the U.S., Celltrion USA announced today that it has signed an agreement with Express Scripts to provids Zymfentra (infliximab-dyyb) Preferred Brand Access on the Express Scripts National Preferred Formulary.
“This agreement opens up an important pathway for access to treatment for millions of patients with chronic diseases,” says Francine Galante, Vice President of Market Access at Celltrion USA, in a news release. “We will continue to work with providers, patients and physicians to build upon our mission of developing transformational therapies that meet the needs of our patients living with chronic debilitating pain.”
